• Home
  • News
  • Learning from incidents: Valproate use by women and girls

Learning from incidents: Valproate use by women and girls

NCL Wide

Valproate is associated with a significant risk of birth defects and developmental disorders in children born to women who take valproate during pregnancy. There have been two incidents of women falling pregnant whilst receiving valproate treatment in NCL. The two practices have shared the incidents and their learning to promote wider awareness.

Healthcare professionals who seek to prescribe valproate to their female patients must make sure they are enrolled in the Pregnancy Prevention Programme. This includes the completion of a signed risk acknowledgement form when their treatment is reviewed by a specialist, at least annually. For further information, see the MHRA guidance.

MMT: Incident summaries

w: https://gps.northcentrallondon.icb.nhs.uk
Expiry date: Sunday, 22 January 2023